# A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors

> **NCT05970497** · PHASE1,PHASE2 · RECRUITING · sponsor: **Krystal Biotech, Inc.** · enrollment: 240 (estimated)

## Conditions studied

- Cancer
- Melanoma Stage III
- Melanoma Stage IV
- Cutaneous Melanoma

## Interventions

- **BIOLOGICAL:** KB707
- **DRUG:** Opdualag
- **DRUG:** KEYTRUDA ®( Pembrolizumab)

## Key facts

- **NCT ID:** NCT05970497
- **Lead sponsor:** Krystal Biotech, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-10-31
- **Primary completion:** 2027-07
- **Final completion:** 2027-07
- **Target enrollment:** 240 (ESTIMATED)
- **Last updated:** 2025-05-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05970497

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05970497, "A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT05970497. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*